Titan Medical Strengthens Robotic Surgery U.S. Patent Portfolio With Grant for Surgical Imaging Technology
September 03 2019 - 8:54AM
Business Wire
Company’s head of intellectual property
recognized by Intellectual Asset Management as a global IP strategy
leader for fifth consecutive year
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD)
(Nasdaq: TMDI), a medical device company focused on the design,
development and commercialization of a robotic surgical system for
application in minimally invasive surgery, announces that it has
been granted U.S. Patent No. 10,398,287, titled “Camera Positioning
System, Method, and Apparatus for Capturing Images During a Medical
Procedure.” The patent is directed at aspects of the Company’s
innovative dual-view camera system for use in robotic surgery,
including single-port robotic surgery.
Titan’s proprietary dual-view camera system consists of an
endoscope module that incorporates a flexible 3D high-definition
camera along with a light source and a camera insertion tube with
an integrated 2D high-definition camera along with an independent
light source. This innovative technology provides surgical teams
with two high-definition options for visualizing the surgical
field, which enhances efficiency and the safety of single-port
robotic surgery. The newly granted patent is directed at the
endoscope module, including its unique modular and flexible design.
This design facilitates convenient camera docking and
intra-operative access, providing the ability to clean the primary
camera lenses during a surgical procedure without undocking from
the robotic surgical system. Additional patent applications
directed at other aspects of the dual-view camera system remain
pending. With this patent grant and the Company’s latest patent
filings, Titan now has 45 patents issued and 82 patent
applications.
Titan also announces that Intellectual Asset Management (“IAM”),
a leading IP business media platform, named Jasminder Brar, the
Company’s Director of Strategic Development and Intellectual
Property, to the 2019 edition of IAM Strategy 300: The World’s
Leading IP Strategists. This is the fifth consecutive year Mr. Brar
has been recognized as a global intellectual property strategy
leader.
IAM Strategy 300: The World’s Leading IP Strategists identifies
the individuals who are leading the way in the development and
implementation of strategies that maximize the value of IP
portfolios. Only those individuals identified through a
confidential nomination process and who further research shows to
have exceptional skill sets, as well as profound insights into the
development, creation and management of IP value, are featured in
the IAM Strategy 300. Listed in the guide are third-party IP
advisers, as well as individuals working inside operating
companies, including technology and medical device companies,
reflecting the importance that businesses across the world place on
in-house IP expertise.
“Titan Medical continues to innovate in single-port robotic
surgery, and we are thrilled with the latest patent grant directed
at our unique dual-view camera system,” said David McNally,
President and CEO of Titan Medical. “We believe our custom-designed
visualization technology will provide unique advantages and address
some of the current challenges with single-port surgery in
particular, and with robotic surgery in general. The strategy
behind this latest patent and our overall approach to corporate IP
is driven by our in-house expertise, and I’m proud to share the
recognition of Jasminder as a leading IP strategist. We are
delighted to have him directing our efforts on this extremely
important aspect of the Company’s commitment to create value for
its stakeholders.”
The 2019 edition of the IAM Strategy 300 guide can be found
here.
About Titan Medical Inc.
Titan Medical Inc. is focused on computer-assisted robotic
surgical technologies for application in MIS. The Company is
developing a single-port robotic surgical system comprised of a
surgeon-controlled patient cart that includes a dual-view camera
system with 3D and 2D high-definition vision options and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an advanced ergonomic interface
to the patient cart and a 3D endoscopic view inside the patient’s
body. Titan intends to initially pursue gynecologic surgical
indications for use of its single-port robotic surgical system.
For more information, please visit the Company’s website at
www.titanmedicalinc.com and on EDGAR at www.sec.gov.
Forward-Looking Statements
This news release contains “forward-looking statements” which
reflect the current expectations of management of the Company’s
future growth, results of operations, performance and business
prospects and opportunities. Wherever possible, words such as
“may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 29, 2019 (which may be viewed at
www.sedar.com and at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190903005541/en/
LHA Investor Relations Kim Sutton Golodetz (212) 838-3777
kgolodetz@lhai.com or Bruce Voss (310) 691-7100 bvoss@lhai.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Sep 2023 to Sep 2024